Predominant right temporal and frontal brain atrophy and progressive behavioral dementia. A case of prion gene

Evangelos Koumasopoulos1, Evangelia Stanitsa1, Efthalia Angelopoulou1

  • 1First Department of Neurology, Eginition University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Neurocase
|April 12, 2025
PubMed
Abstract

Insights

A rare prion protein gene (PRNP) mutation caused frontotemporal dementia (FTD) in a Greek patient with a family history. Genetic testing is crucial for diagnosing behavioral variant FTD (bvFTD) with a dementia family history.

Area of Science:

  • Neurogenetics
  • Neurology
  • Dementia Research

Background:

  • Frontotemporal dementia (FTD) is a rare neurodegenerative disorder, often hereditary, typically manifesting before age 65.
  • Mutations in the prion protein gene (PRNP) are an exceptionally rare cause of FTD, usually associated with Creutzfeldt-Jakob disease.
  • The clinical presentation and genetic basis of PRNP-linked FTD remain incompletely understood, with no prior reports in the Greek population.

Purpose of the Study:

  • To report a novel case of FTD in a Greek patient with a PRNP gene mutation.
  • To describe the clinical phenotype and genetic findings in a patient with probable behavioral variant FTD (bvFTD).
  • To highlight the importance of genetic screening for PRNP mutations in specific FTD cases.

Main Methods:

  • Clinical assessment of a patient presenting with probable bvFTD and a positive family history of dementia.
  • Genetic analysis to identify mutations in the PRNP gene.
  • Phenotypic characterization of the identified PRNP mutation.

Main Results:

  • A patient with probable bvFTD and a family history of dementia was identified.
  • A heterozygous c.623G>A (p.Arg208His) mutation in the PRNP gene was detected in the patient.
  • This mutation was identified as the likely cause of the FTD phenotype.

Conclusions:

  • The PRNP gene mutation p.Arg208His is associated with an FTD phenotype.
  • Genetic testing for PRNP mutations should be considered in patients with bvFTD and a positive family history of dementia.
  • This case expands the known spectrum of genetic FTD and provides the first description of a PRNP mutation in the Greek population.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
336
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
334
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
132
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K